Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn’s Disease Patients: The SUSTAIN Study
暂无分享,去创建一个
J. Gisbert | I. Bastón-Rey | D. Busquets | M. Chaparro | F. García-Alonso | M. Cabello | C. Taxonera | J. Gordillo | F. Bermejo | M. Martín-Arranz | F. Argüelles-Arias | S. Sulleiro | I. Marín-Jiménez | D. Ginard | M. Barreiro-de Acosta | P. Varela | D. Monfort | E. Vispo | R. Pajares Villarroya | Y. González-Lama | M. van Domselaar | R. de Francisco | E. Fernández-Salgado | L. Ramos | M. Bosca-Watts | C. Rubín de Célix | A. S. San Román | María José García | E. Hinojosa | P. Martínez Montiel | A. Hernández Camba | N. Jiménez | M. Arroyo | J. González García | M. D. Diz-Lois Palomares | E. Iglesias Flores | S. Rubio Iturria | A. Núñez Ortiz | M. Charro | C. Dueñas Sadornil | O. Merino Ochoa | E. Iyo | A. Gutiérrez Casbas | P. Ramírez de la Piscina | B. Velayos Jiménez | C. Quílez Ivorra | J. M. Vázquez Morón | José María Huguet | A. M. Muñagorri Santos | V. Amo | J. Martínez Cadilla | P. Fradejas Salazar | S. García López | A. Figuerola | I. Jiménez | F. J. Martínez Cerezo | G. Molina Arriero | Alejandro Núñez | F. Rodríguez Moranta | V. Robles Alonso | M. M. M. Martín Rodríguez | Patricia Camo-Monterde | I. García Tercero | Mercè Navarro Llavat | L. Arias García | D. Hervías Cruz | Cynthia Novella | M. Boscá-Watts | M. J. García | M. Navarro Llavat | C. Novella | Saioa Rubio Iturria
[1] J. Allegretti,et al. Predictors of Ustekinumab Failure in Crohn's Disease After Dose Intensification. , 2020, Inflammatory bowel diseases.
[2] B. Sands,et al. Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies , 2020, Inflammatory bowel diseases.
[3] Philip Smith,et al. Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti‐TNF‐refractory Crohn’s disease , 2020, Alimentary pharmacology & therapeutics.
[4] B. Flourié,et al. Effectiveness And Safety Of Ustekinumab Intensification At 90 Mg Every Four Weeks In Crohn's Disease: A Multicenter Study. , 2020, Journal of Crohn's & colitis.
[5] D. D. de Jong,et al. Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatment , 2020, Alimentary pharmacology & therapeutics.
[6] Shannon Chang,et al. Ustekinumab Does Not Increase Risk of Adverse Events: A Meta-Analysis of Randomized Controlled Trials , 2020, Digestive Diseases and Sciences.
[7] C. Lees,et al. Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard‐dose subcutaneous maintenance therapy , 2020, Alimentary pharmacology & therapeutics.
[8] A. Amiot,et al. The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti‐tumour necrosis factor , 2020, Alimentary pharmacology & therapeutics.
[9] Elizabeth A. Scoville,et al. A Single Center Experience With Long-Term Ustekinumab Use and Reinduction in Patients With Refractory Crohn Disease , 2020, Crohn's & colitis 360.
[10] M. Regueiro,et al. Safety considerations with biologics and new inflammatory bowel disease therapies. , 2019, Current opinion in gastroenterology.
[11] M. Cottone,et al. Effectiveness and safety of Ustekinumab for the treatment of Crohn’s disease in real-life experiences: a meta-analysis of observational studies , 2019, Expert opinion on biological therapy.
[12] J. M. Nerín de la Puerta,et al. Efficacy and safety of ustekinumab in real clinical practice. Retrospective multicentre study. ARAINF cohort. , 2019, Gastroenterologia y hepatologia.
[13] L. Stassen,et al. ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. , 2019, Journal of Crohn's & colitis.
[14] R. Eliakim,et al. Effectiveness and safety of Ustekinumab for Crohn's disease; systematic review and pooled analysis of real-world evidence. , 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[15] S. McCartney,et al. Biologic therapies for Crohn’s disease: optimising the old and maximising the new , 2019, F1000Research.
[16] J. Gisbert,et al. Real‐world short‐term effectiveness of ustekinumab in 305 patients with Crohn’s disease: results from the ENEIDA registry , 2019, Alimentary pharmacology & therapeutics.
[17] D. D. de Jong,et al. Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study , 2019, Journal of Crohn's & colitis.
[18] R. Nissinen,et al. Ustekinumab for Crohn’s disease: a nationwide real-life cohort study from Finland (FINUSTE) , 2019, Scandinavian journal of gastroenterology.
[19] P. Rutgeerts,et al. IM-UNITI: 3 Year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. , 2019, Journal of Crohn's & colitis.
[20] L. Downey,et al. Early real-world effectiveness of ustekinumab for Crohn’s disease , 2019, Frontline Gastroenterology.
[21] Z. Ran,et al. Loss of response to scheduled infliximab therapy for Crohn's disease in adults: A systematic review and meta‐analysis , 2019, Journal of digestive diseases.
[22] M. Neurath,et al. Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease. , 2018, The lancet. Gastroenterology & hepatology.
[23] Siddharth Singh,et al. Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease. , 2018, Inflammatory bowel diseases.
[24] C. Hewitt,et al. Quality of Life in Inflammatory Bowel Disease: A Systematic Review and Meta-analyses-Part II. , 2018, Inflammatory bowel diseases.
[25] Esmirrá Isabella Tomazoni,et al. SYMPTOMS OF ANXIETY AND DEPRESSION, AND QUALITY OF LIFE OF PATIENTS WITH CROHN'S DISEASE. , 2018, Arquivos de gastroenterologia.
[26] A. Amiot,et al. Long‐term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience , 2018, Alimentary pharmacology & therapeutics.
[27] S. Targan,et al. LONG-TERM EFFICACY AND SAFETY OF USTEKINUMAB FOR CROHN’S DISEASE: RESULTS FROM IM-UNITI LONG-TERM EXTENSION THROUGH 2 YEARS , 2017 .
[28] B. Bressler,et al. Ustekinumab use in Crohn’s disease: a Canadian tertiary care centre experience , 2017, Scandinavian journal of gastroenterology.
[29] A. Cohen,et al. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn’s Disease , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[30] Z. Zeng,et al. Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn’s disease , 2017, Journal of Gastroenterology.
[31] D. Jayne,et al. Summary of product characteristics , 2016 .
[32] Dawn B. Beaulieu,et al. Patients with Refractory Crohn's Disease Successfully Treated with Ustekinumab , 2016, Inflammatory bowel diseases.
[33] S. Jick,et al. Inflammatory Bowel Disease and the Risk of Autoimmune Diseases. , 2016, Journal of Crohn's & colitis.
[34] W. Sandborn,et al. Crohn's disease , 2012, The Lancet.
[35] G. Greenberg,et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. , 2012, The New England journal of medicine.
[36] L. Peyrin-Biroulet,et al. Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review , 2011, The American Journal of Gastroenterology.
[37] L. Peyrin-Biroulet,et al. The Natural History of Adult Crohn's Disease in Population-Based Cohorts , 2010, The American Journal of Gastroenterology.
[38] R. Xavier,et al. Unravelling the pathogenesis of inflammatory bowel disease , 2007, Nature.
[39] R. Wright. Crohn's disease: diagnosis and management. , 1985, Comprehensive therapy.
[40] J. Gisbert,et al. New molecules in the treatment of inflammatory bowel disease , 2019 .
[41] H. Tilg,et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1 Diagnosis and Medical Management , 2017, Journal of Crohn's & colitis.
[42] P. Rutgeerts,et al. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. , 2016, The New England journal of medicine.